Conference Slides

Day 1

Hormones and the fountain of youth
Adriane Fugh-Berman MD, Georgetown University Medical Center
Tony Scialli MD, George Washington University

The endangered normal: Does anyone escape a diagnosis?
Adriane Fugh-Berman MD, Georgetown University Medical Center

Demented patients and difficult behaviors
Tom Finucane MD, Johns Hopkins School of Medicine

How safe are we? Health Canada and drug safety
Joel Lexchin MD MSc, York University

The impact of pricing of specialty drugs on care, coverage... and just about everything else
Sharon Levine MD, Kaiser-Permanente

The high price of a "free" market: Medicines pricing in the US and beyond
Ruth Lopert MD, George Washington University

Getting better in light of political realities
Louis Jacques MD, ADVI

What are the rules of the road? FDA law and regulations for reviews of drug and biological practices
John Powers MD, George Washington University

Day 2

Managing chronic pain: A case study of the potential of comparative effectiveness research
Carolyn Clancy MD, Department of Veterans Affairs

The opioid addiction epidemic: How marketing and regulartory failure led to a public health crisis
Andrew Kolodny MD, Physicians for Responsible Opioid Prescribing

Hyperglycemia, sedentary obesity and complications of type 2 diabetes
Tom Finucane MD, Johns Hopkins School of Medicine

Should black box warnings for fluoroquinolones be revised: Is the bar set too high?
Charles Bennett MD PhD, University of South Carolina

The risks of newer anticoagulants: Sales vs safety
Thomas Moore, Institute for Safe Medication Practices

Researchers behaving badly: Misconduct in clinical trials
Charles Seife, New York University

Psychiatry under the influence: Institutional corruption and diagnostic and practice guidelines
Lisa Cosgrove PhD, University of Massachusetts-Boston

Changes in medical students' responses to drug company marketing
Frederick Sierles MD, Rosalind Franklin University of Medicine and Science